TCW Group Inc. Purchases 92,970 Shares of Pfizer Inc. (NYSE:PFE)

TCW Group Inc. lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 82.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 205,376 shares of the biopharmaceutical company’s stock after acquiring an additional 92,970 shares during the quarter. TCW Group Inc.’s holdings in Pfizer were worth $5,913,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. GoalVest Advisory LLC grew its position in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares during the period. VisionPoint Advisory Group LLC boosted its position in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. Tennessee Valley Asset Management Partners bought a new stake in Pfizer in the fourth quarter valued at about $36,000. DiNuzzo Private Wealth Inc. acquired a new position in Pfizer in the fourth quarter valued at about $37,000. Finally, Life Planning Partners Inc acquired a new position in shares of Pfizer during the 4th quarter worth about $39,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 0.7 %

Shares of NYSE:PFE traded up $0.19 during midday trading on Friday, hitting $28.88. The stock had a trading volume of 22,589,127 shares, compared to its average volume of 44,974,800. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The business’s 50-day simple moving average is $27.27 and its 200-day simple moving average is $27.96. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37. The company has a market cap of $163.65 billion, a P/E ratio of -481.25, a PEG ratio of 1.13 and a beta of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. The company had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company’s quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.23 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.82%. Pfizer’s payout ratio is -2,799.53%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on PFE shares. Morgan Stanley lifted their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.